Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 13/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 5/20 | 0.46 |
| ▸ | ILK | Q13418 | 2/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15708092 | 0.98 | DYRK1A (0.48) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL17484182 | 0.84 | NPC1 (0.58) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL7082892 | 0.84 | DYRK1A (0.49) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL360373 | 0.84 | DYRK1A (0.49) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL3265720 | 0.84 | LOXL2 (0.59) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| Hydrochloric Acid SCHEMBL30209135 | 0.83 | LOXL2 (0.58) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL4900594 | 0.81 | ILK (0.47) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL5632209 | 0.81 | DYRK1A (0.50) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL20254213 | 0.81 | DYRK1A (0.50) | DYRK1AAKR1B1TRPV1AKR1A1ILK | |
| SCHEMBL20964606 | 0.80 | DYRK1A (0.49) | DYRK1AAKR1B1TRPV1AKR1A1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-05-22 | — | — | US | disclosed |
| CN-118684676-A | Heterocyclic compound, and preparation method and application thereof | 上海济煜医药科技有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| CN-115160339-B | Aldose reductase inhibitors and methods of use thereof | 纽约市哥伦比亚大学理事会 | 2024-05-14 | — | — | CN | disclosed |
| EP-4316603-A2 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3757107-B1 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | UNIV COLUMBIA (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3757107-B1 | 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | UNIV COLUMBIA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-5075442-A | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof | PFIZER INC. (US) | 1991-12-24 | — | — | US | disclosed |
| WO-1991017163-A1 | IMIDAZO (4,5-c) PYRIDINES WITH PAF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1991-11-14 | — | — | WO | disclosed |
| US-4996204-A | Antidiabetic agents | PFIZER INC. (US) | 1991-02-26 | — | — | US | disclosed |
| EP-0401981-A1 | Pyridazinone deriratives | PFIZER INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| EP-0397350-A1 | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof | PFIZER INC. (US) | 1990-11-14 | — | — | EP | disclosed |
| US-4954629-A | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof | PFIZER INC. (US) | 1990-09-04 | — | — | US | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| US-4748280-A | Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6) | PFIZER INC. (US) | 1988-05-31 | — | — | US | disclosed |
| US-4723010-A | Process for preparing chloromethyl thiazoles or oxazoles, and intermediates for use therein | PFIZER INC. (US) | 1988-02-02 | — | — | US | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163073-A1 | ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 4217/4885AKR1B1 2/4885TRPV1 2486/4885 |
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | DYRK1A 3857/4885AKR1B1 2/4885TRPV1 3283/4885 |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | DYRK1A 2189/4885AKR1B1 3195/4885TRPV1 4874/4885 |
| US-12077547-B2 | Aldose reductase inhibitors and methods of use thereof | ALDOA, AKR1B1, AKR1C2 | DYRK1A 4217/4885AKR1B1 2/4885TRPV1 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.